PD-L1 SP263 Media Release

Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced approval of the VENTANA PD-L1 (SP263) Assay by the U.S. Food and Drug Administration (FDA) as a complementary diagnostic3 to provide PD-L1 status for patients with locally advanced or metastatic urothelial carcinoma (mUC)4 who are being considered for treatment with the FDA-approved anti-PD-L1 immunotherapy IMFINZI™ (durvalumab, AstraZeneca).